SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3 2024. SCY-247 preclinical studies were presented at medical conferences and continue to show potent and broad antifungal activity. Phase 1 study initiation is anticipated in Q4 2024. SCYNEXIS ended Q3 2024 with cash, cash equivalents and investments of $84.9 million, including the recently earned $10.0 million development milestone, and projects a cash runway into Q3 2026. SCYNEXIS will attend Guggenheim's Inaugural Global Healthcare Conference in Boston on November 12tha
11/6/24 4:30:00 PM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET. Maxim Healthcare Virtual Summit Details: Format:Fireside chatDate:Thursday, October 17, 2024Time:11:30 A.M. ETLocation:Virtual To sign up to view the presentation, click here. 1x1 investor meetings will be available after the event upon request through the following link or by conta
10/10/24 8:00:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024. Presentation details can be found below: Oral Presentation: Title:Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal InfectionsSession:Mycology Matters: Insights into Fungal InfectionsDate/Time:Thursday October 17,
10/3/24 8:00:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i
3/30/23 7:05:00 AM ET
$GSK
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3
11/9/22 7:00:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast: LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'
11/1/22 8:30:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care

$SCYX
Leadership Updates

Live Leadership Updates

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th
7/24/23 8:00:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c
5/17/21 8:30:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p
5/11/21 8:30:00 AM ET
$SCYX
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

Products on NDA 214900

Approval Date(s) and History, Letters, Labels, Reviews for NDA 214900

Supplements

Chat with this insight

Recent Analyst Ratings for $SCYX

$SCYX Press Releases

Fastest customizable press release news feed in the world

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

$SCYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

Director Macdonald Guy was granted 23,000 shares, increasing direct ownership by 72% to 55,000 units (SEC Form 4)

Director Hastings David C was granted 23,000 shares, increasing direct ownership by 99% to 46,183 units (SEC Form 4)

$SCYX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SCYX Market Insights

Live Market Insights

$SCYX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Aegis Capital reiterated coverage on SCYNEXIS with a new price target

Aegis Capital reiterated coverage on SCYNEXIS with a new price target

Maxim Group reiterated coverage on SCYNEXIS with a new price target

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate

SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 At The Congress Of The European Society Of Clinical Microbiology And Infectious Diseases

Cantor Fitzgerald Reiterates Overweight on SCYNEXIS

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

$SCYX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

$SCYX SEC Filings

SCYNEXIS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by SCYNEXIS Inc.

SEC Form 10-Q filed by SCYNEXIS Inc.

$SCYX Financials

Live finance-specific insights

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

$SCYX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

$SCYX Leadership Updates

Live Leadership Updates

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

Recent Analyst Ratings for
$SCYX

$SCYX
Press Releases

$SCYX
Insider Trading

$SCYX
Analyst Ratings

$SCYX
Market Insights

$SCYX
Insider Purchases

$SCYX
FDA approvals

$SCYX
SEC Filings

$SCYX
Financials

$SCYX
Large Ownership Changes

$SCYX
Leadership Updates